Time Resolved Fluorescence based HTS to Detect Structural Changes in cTnI

Case ID:

This innovation involves the development of a probe that attaches to a specific protein called cardiac troponin I (cTnI), which is involved in muscle contraction of the heart. This probe, created through genetic engineering techniques, is designed to detect changes in cTnI's neighboring protein, cardiac troponin T (cTnT). When there's a change in cTnT, it alters the environment around cTnI, which the probe can detect by changes in fluorescence. Essentially, the probe acts like a sensor that fluoresces when it detects certain changes in the heart muscle. The purpose of this innovation is to aid in the validation of potential drug candidates for treating a heart condition called hypertrophic cardiomyopathy (HCM). By using this probe, researchers can observe how different drugs affect the interaction between cTnI and cTnT. This information helps in understanding the effectiveness of drugs in treating HCM, a condition characterized by thickening of the heart muscle, and may lead to the development of improved treatment options for patients with this condition.

This technology is addressing the need for better methods to understand and treat hypertrophic cardiomyopathy (HCM). HCM is a condition where the heart muscle becomes abnormally thick, leading to potential complications such as arrhythmias and heart failure. Current solutions for studying HCM involve various methods, including genetic testing, imaging techniques like echocardiography, and medications to manage symptoms. However, these methods often fall short in providing a detailed understanding of the molecular changes underlying HCM and assessing the effectiveness of potential treatments. The innovation here lies in the development of a probe that specifically targets cardiac troponin I (cTnI) and detects changes in its neighboring protein, cardiac troponin T (cTnT), at a molecular level. This probe offers a more direct and precise method to monitor the interaction between these proteins, which is crucial in understanding the mechanisms of HCM and evaluating drug candidates. Unlike current methods, which may lack specificity or provide indirect measurements, this probe-based approach offers real-time, molecular-level insights into the dynamics of the heart muscle, potentially leading to more effective treatments for HCM. It provides a way to observe subtle changes in protein interactions that may not be easily detectable with conventional techniques, offering a promising avenue for both research and clinical applications in managing HCM.


  • Treatment for hypertrophic cardiomyopathy (HCM)
  • Cardiology
  • Biomedical research


  • Provides real-time monitoring of molecular changes in the heart muscle, offering a deeper understanding of hypertrophic cardiomyopathy (HCM) compared to conventional methods.
  • Enables precise assessment of potential drug candidates for treating HCM by directly 
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
Romi Castillo
Jil Tardiff